Opendata, web and dolomites

VOGAS SIGNED

Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VOGAS project word cloud

Explore the words cloud of the VOGAS project. It provides you a very rough idea of what is the project "VOGAS" about.

validated    gastric    enrolled    ms    dysplasia    america    composition    patients    analyser    headspace    invasive    coupled    competences    electronic    mechanisms    schemes    vocs    gas    vital    burden    gc    optimized    geographical    prototypes    metaplasia    countries    parallel    american    gold    first    members    lines    spectroscopic    colombia    origin    sensors    clinical    atrophy    cell    panels    detecting    stage    compounds    cured    latin    utilizing    chile    tissue    mass    lack    international    compact    flora    obtaining    cancer    pylori    volatile    device    expertise    concentration    breath    voc    acquired    screening    individuals    brazil    collaborations    tool    metal    oxide    chances    confounding    intestinal    infrared    components    nanoparticles    mid    building    ukraine    portable    nose    exhaled    precancerous    diagnosed    eastern    orthogonal    spectrometry    techniques    dimensional    combine    good    disease    human    analytical    data    chromatography    organic    lesions    latvia    previously    bacterial    infection   

Project "VOGAS" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙781˙179 €
 EC max contribution 3˙781˙179 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 650˙363.00
2    LATVIJAS UNIVERSITATE LV (RIGA) participant 510˙000.00
3    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 395˙535.00
4    UNIVERSITAET ULM DE (ULM) participant 385˙000.00
5    JLM INNOVATION GMBH DE (TUEBINGEN) participant 375˙000.00
6    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 358˙875.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 253˙727.00
8    UNIVERSIDAD DE PAMPLONA CO (PAMPLONA) participant 250˙625.00
9    NATIONAL CANCER INSTITUTE UA (KIYV) participant 210˙000.00
10    HOSPITAL UNIVERSITARIO SAN IGNACIO CO (BOGOTA) participant 209˙984.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 182˙068.00
12    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00

Map

 Project objective

Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.

This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).

Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.

The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.

As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOGAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOGAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More